Project Grant R01DK141523
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,192,362 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Averto Medical Inc., a medical device manufacturer in Fremont, California. The grant supports a safety and efficacy clinical trial of Averto's COLOSEAL ICD System, a minimally invasive medical device designed as an alternative to temporary ostomies for the surgical treatment of...
- This Project Grant award of $250,056.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is supporting a pilot study at the University of North Carolina at Chapel Hill (UNC-CH) to evaluate the feasibility, safety, and tolerability of using the antibiotic rifaximin for the secondary prevention of pouchitis recurrence. The study aims to demonstrate the feasibility of...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $200,660 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Albert Einstein College of Medicine. The grant will fund the development and testing of a mobile health application for a digital mind-body intervention (DMBI) targeted at improving psychological distress and quality-of-life among Black and Hispanic patients with inflammatory bowel disease...
- This $146,922 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The University of Pittsburgh is conducting research to investigate the role of gut protist-derived compounds on dietary antigen presenting dendritic cells in celiac disease. The project aims to understand how certain gut microbes can protect against virus-mediated loss of oral...
- This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) totals $167,768 and aims to evaluate whether beta-lactam antibiotics increase the risk of acute kidney injury (AKI) in patients receiving immune checkpoint inhibitor (ICI) cancer treatments, compared to fluoroquinolone antibiotics. The award will support a target trial emulation study to assess this...
- This $2,842,245 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to elucidate the role of intestinal epithelial cell (IEC) injury pathways in governing anti-TNF therapy effectiveness for ulcerative colitis. The project aims to identify predictive biomarkers in formalin-fixed, paraffin-embedded (FFPE) patient biopsies that...
- This federal Project Grant award, in the amount of $531,999.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award is supporting research focused on understanding the role of alternative splicing in the proximal tubules of the kidney and its relationship to the progression of diabetic kidney disease. The research will investigate how diabetes...
- This federal Project Grant award, with a total funding amount of $645,617, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant is aimed at understanding the dysfunction of hematopoietic stem cells in refractory Crohn's disease, a condition that is resistant to traditional treatments. The research will profile hematopoietic stem cell populations...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Vanderbilt University Medical Center (VUMC) a $150,000 Project Grant under CFDA 93.847, the Diabetes, Digestive, and Kidney Diseases Extramural Research program. The grant, which runs from Sep 1, 2023 to Aug 31, 2024, will fund a study to identify factors that contribute to clonal expansion and disease progression in clonal hematopoiesis of indeterminate potential (CHIP). The research aims to dissect the...
- This Project Grant award, in the amount of $126,846, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports a translational research project to investigate the role of the gut microbiome in the pathogenesis of sepsis-associated acute kidney injury (AKI). The research, to be conducted at the University of Michigan, aims to identify gut bacteria...
This federal Project Grant award of $1,050,000.00 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a pilot, randomized clinical trial to compare the use of placebo versus antibiotic treatment for 100 patients with acute uncomplicated diverticulitis at Vanderbilt University Medical Center (VUMC) in Nashville, TN. The trial aims to determine the differential rates of recruitment, treatment adherence, and clinical outcomes by race and ethnicity, with the goal of addressing a key knowledge gap in the US about the necessity of antibiotic therapy for this condition. The award period runs from September 12, 2025 to September 11, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.1m | 9/11/25 |